Lower the price or we won't pay, NHS tells Vertex in Orkambi row

The UK’s National Health Service (NHS) and the company leading drug development in cystic fibrosis (CF) remain at loggerheads.

Both sides claim that the pricing mechanisms being employed by the other are not viable in a situation has led to UK politicians, patients and charities expressing their despair.

"The scale of parliamentary engagement in this debate echoes and amplifies the CF community’s sense of urgency on access to new Vertex medicines"